SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences informs about post results conference call

16 May 2022 Evaluate

Zydus Lifesciences has informed that the financial results of the company for Q4 2021-22 (January-March 2022) would be declared on May 20, 2022. Post results Q&A session through webinar (powered by Zoom) has been scheduled on the same day- May 20, 2022 at 5:00 pm. Sharvil Patel, Managing Director of the Company would be hosting the call and the details to join the call is provided in the attached file.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

929.25 0.40 (0.04%)
22-Apr-2026 13:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1663.10
Dr. Reddys Lab 1224.45
Cipla 1235.20
Zydus Lifesciences 929.25
Lupin 2310.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×